Evidence map›Paper›PMID 40377262›Full record

ArticleThe Journal of urology2025

Restriction Spectrum Imaging as a Quantitative Biomarker for Prostate Cancer With Reliable Positive Predictive Value.

Mariluz Rojo Domingo, Deondre D Do, Christopher C Conlin, Aditya Bagrodia, Tristan Barrett, Madison T Baxter, Matthew Cooperberg, Felix Feng, Michael E Hahn, Mukesh Harisinghani and 33 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Urethra contours on MRI: Multidisciplinary consensus educational atlas and reference standard for artificial intelligence benchmarking.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

43 authors.

Mariluz Rojo DomingoDepartment of Bioengineering, University of California San Diego, La Jolla, California.ORCID 0000-0003-1386-4636
Deondre D DoDepartment of Bioengineering, University of California San Diego, La Jolla, California.
Christopher C ConlinDepartment of Radiology, University of California San Diego, La Jolla, California.
Aditya BagrodiaDepartment of Urology, University of California San Diego, La Jolla, California.
Tristan BarrettDepartment of Radiology, University of Cambridge, Cambridge, United Kingdom.
Madison T BaxterDepartment of Radiation Medicine, University of California San Diego, La Jolla, California.
Matthew CooperbergDepartment of Urology, University of California San Francisco, San Francisco, California.
Felix FengDepartment of Radiation Oncology, University of California San Francisco, San Francisco, California.
Michael E HahnDepartment of Radiology, University of California San Diego, La Jolla, California.
Mukesh HarisinghaniDepartment of Radiology, Massachusetts General Hospital, Boston, Massachusetts.
Gary HollenbergDepartment of Clinical Imaging Sciences, University of Rochester Medical Center, Rochester, New York.
Juan Javier-DeslogesDepartment of Urology, University of California San Diego, La Jolla, California.
Karoline KallisDepartment of Radiation Medicine, University of California San Diego, La Jolla, California.
Sophia KamranDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.
Christopher J KaneDepartment of Urology, University of California San Diego, La Jolla, California.
Dimitri KesslerDepartment of Radiology, University of Cambridge, Cambridge, United Kingdom.
Joshua KupermanDepartment of Radiation Medicine, University of California San Diego, La Jolla, California.
Kang-Lung LeeDepartment of Radiology, University of Cambridge, Cambridge, United Kingdom.
Jonathan LevineDepartment of Urology, University of California San Francisco, San Francisco, California.
Michael A LissDepartment of Urology, University of Texas Health Sciences Center San Antonio, San Antonio, Texas.
Daniel J A MargolisDepartment of Radiology, Weill Cornell Medicine, New York, New York.
Ian MatthewsDepartment of Radiation Medicine, University of California San Diego, La Jolla, California.
Paul M MurphyDepartment of Radiology, University of California San Diego, La Jolla, California.
Nabih NakrourDepartment of Radiology, Massachusetts General Hospital, Boston, Massachusetts.
Michael OhligerDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California.
Courtney OllisonDepartment of Radiation Medicine, University of California San Diego, La Jolla, California.
Thomas OsinskiDepartment of Urology, University of Rochester Medical Center, Rochester, New York.
Anthony James PamatmatDepartment of Urology, University of Rochester Medical Center, Rochester, New York.
Isabella R PompaDepartment of Radiology, Massachusetts General Hospital, Boston, Massachusetts.
Rebecca Rakow-PennerDepartment of Radiology, University of California San Diego, La Jolla, California.
Jacob L RobertsDepartment of Urology, University of California San Diego, La Jolla, California.
Ahmed S ShabaikDepartment of Pathology, University of California San Diego, La Jolla, California.
Yuze SongDepartment of Radiation Medicine, University of California San Diego, La Jolla, California.
David SongDepartment of Urology, University of Rochester Medical Center, Rochester, New York.
Clare M TempanyDepartment of Radiology, Massachusetts General Hospital, Boston, Massachusetts.
Shaun TrecartenDepartment of Urology, University of Texas Health Sciences Center San Antonio, San Antonio, Texas.
Natasha WehrliDepartment of Radiology, Weill Cornell Medicine, New York, New York.
Eric P WeinbergDepartment of Clinical Imaging Sciences, University of Rochester Medical Center, Rochester, New York.
Sean WoolenDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California.
George XuDepartment of Radiation Medicine, University of California San Diego, La Jolla, California.
Allison Y ZhongDepartment of Radiation Medicine, University of California San Diego, La Jolla, California.
Anders M DaleDepartment of Radiology, University of California San Diego, La Jolla, California.
Tyler M SeibertDepartment of Bioengineering, University of California San Diego, La Jolla, California.ORCID 0000-0002-4089-7399

Funding

San Diego Clinical and Translational Research InstituteUL1TR000100 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S · 2012 to 2015
$19.7M
Validation, Calibration, and Translation of Restriction Spectrum Imaging Signal Maps to enhance MRI diagnostic capabilities in Prostate CancerR01CA279667 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Michael Andre Liss, Nathan Scott White · 2023 to 2026
$2.4M
Improving assessment of prostate cancer bone metastases using advanced diffusion imagingK08EB026503 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SEIBERT, TYLER MICHAEL · 2019 to 2022
$805k
NCATS NIH HHS UL1 TR000100NCI NIH HHS R01 CA279667NIBIB NIH HHS K08 EB026503
6 · The paper itself

Abstract

purposeThe positive predictive value of the Prostate Imaging Reporting and Data System (PI-RADS) for clinically significant prostate cancer (csPCa, grade group [GG] ≥2) varies widely between radiologists. The restriction spectrum imaging restriction score (RSIrs) is a biophysics-based metric derived from diffusion MRI that could be an objectively interpretable biomarker for csPCa. We aimed to evaluate performance of RSIrs for patient-level detection of csPCa in a large and heterogenous dataset, and to combine RSIrs with clinical and imaging parameters for csPCa detection. MATERIALS AND

methodsAt 7 centers, participants underwent prostate MRI between January 2016 and March 2024. We calculated patient-level csPCa probability based on maximum RSIrs in the prostate and compared patient-level csPCa detection to apparent diffusion coefficient (ADC) and PI-RADS using AUC. We also evaluated csPCa discrimination by GG and combining RSIrs with clinical risk factors through multivariable regression.

resultsAmong patients who met the inclusion criteria (n = 1892), probability of csPCa increased with higher RSIrs. Among biopsy-naïve patients (n = 877), AUCs for GG ≥ 2 vs non-csPCa were RSIrs = 0.73 (0.69-0.76), ADC = 0.54 (0.50-0.57), and PI-RADS = 0.75 (0.71-0.78). RSIrs significantly outperformed ADC (

conclusionsRSIrs is an accurate and reliable quantitative biomarker that performs better than conventional ADC and comparably with expert-defined PI-RADS for patient-level detection of csPCa. RSIrs provides objective estimates of probability of csPCa that do not require radiology expertise.

Indexed as

Diffusion Magnetic Resonance ImagingProstateProstatic NeoplasmsAgedHumansMaleMiddle AgedNeoplasm GradingPredictive Value of TestsRetrospective Studiesdiffusion-weighted imagingprostate cancer detectionprostate MRIquantitative biomarkerrestriction spectrum imaging

Identifiers

PMID40377262
PMCPMC12334330

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.